200,000+ products from a single source!
sales@angenechem.com
Home > Indoles and Oxindole > 204005-46-9
204005-46-9 | 2H-Indol-2-one, 3-[(3,5-dimethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro-
CAS No: 204005-46-9 Catalog No: AG00298W MDL No:MFCD01940922
Product Description
Catalog Number:
AG00298W
Chemical Name:
2H-Indol-2-one, 3-[(3,5-dimethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro-
CAS Number:
204005-46-9
Molecular Formula:
C15H14N2O
Molecular Weight:
238.2845
MDL Number:
MFCD01940922
IUPAC Name:
(3Z)-3-[(3,5-dimethyl-1H-pyrrol-2-yl)methylidene]-1H-indol-2-one
InChI:
InChI=1S/C15H14N2O/c1-9-7-10(2)16-14(9)8-12-11-5-3-4-6-13(11)17-15(12)18/h3-8,16H,1-2H3,(H,17,18)/b12-8-
InChI Key:
WUWDLXZGHZSWQZ-WQLSENKSSA-N
SMILES:
O=C1Nc2c(C1=Cc1[nH]c(cc1C)C)cccc2
UNII:
71IA9S35AJ
NSC Number:
696819
Properties
Complexity:
377
Compound Is Canonicalized:
Yes
Covalently-Bonded Unit Count:
1
Defined Atom Stereocenter Count:
0
Defined Bond Stereocenter Count:
1
Exact Mass:
238.111g/mol
Formal Charge:
0
Heavy Atom Count:
18
Hydrogen Bond Acceptor Count:
1
Hydrogen Bond Donor Count:
2
Isotope Atom Count:
0
Molecular Weight:
238.29g/mol
Monoisotopic Mass:
238.111g/mol
Rotatable Bond Count:
1
Topological Polar Surface Area:
44.9A^2
Undefined Atom Stereocenter Count:
0
Undefined Bond Stereocenter Count:
0
XLogP3:
2.5
Literature
| Title | Journal |
|---|---|
| Tumor-promoting and pro-angiogenic effects of roxarsone via VEGFR2/PLCγ/PKC signaling. | Chemico-biological interactions 20180825 |
| Why are most phospholipidosis inducers also hERG blockers? | Archives of toxicology 20171201 |
| The aryl hydrocarbon receptor is required for induction of p21cip1/waf1 expression and growth inhibition by SU5416 in hepatoma cells. | Oncotarget 20170411 |
| Bromodomain-Containing Protein 4: The Epigenetic Origin of Pulmonary Arterial Hypertension. | Circulation research 20150828 |
| Caveolin-1 is a negative regulator of NADPH oxidase-derived reactive oxygen species. | Free radical biology & medicine 20140801 |
| NADPH oxidase 4 is expressed in pulmonary artery adventitia and contributes to hypertensive vascular remodeling. | Arteriosclerosis, thrombosis, and vascular biology 20140801 |
| Identification of potent Yes1 kinase inhibitors using a library screening approach. | Bioorganic & medicinal chemistry letters 20130801 |
| A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. | The Biochemical journal 20130415 |
| Resveratrol ameliorates high-glucose-induced hyperpermeability mediated by caveolae via VEGF/KDR pathway. | Genes & nutrition 20130301 |
| Vitamin D improves the angiogenic properties of endothelial progenitor cells. | American journal of physiology. Cell physiology 20121101 |
| Leptin induces tube formation in first-trimester extravillous trophoblast cells. | European journal of obstetrics, gynecology, and reproductive biology 20120901 |
| Novel tricyclic indeno[2,1-d]pyrimidines with dual antiangiogenic and cytotoxic activities as potent antitumor agents. | Bioorganic & medicinal chemistry 20120715 |
| VEGF regulates antidepressant effects of lamotrigine. | European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology 20120601 |
| N⁴-(3-Bromophenyl)-7-(substituted benzyl) pyrrolo[2,3-d]pyrimidines as potent multiple receptor tyrosine kinase inhibitors: design, synthesis, and in vivo evaluation. | Bioorganic & medicinal chemistry 20120401 |
| Study of differences in the VEGFR2 inhibitory activities between semaxanib and SU5205 using 3D-QSAR, docking, and molecular dynamics simulations. | Journal of molecular graphics & modelling 20120201 |
| N⁴-Aryl-6-substitutedphenylmethyl-7H-pyrrolo[2,3-d]pyrimidine-2,4-diamines as receptor tyrosine kinase inhibitors. | Bioorganic & medicinal chemistry 20120115 |
| Inhibitory effects of SU5416, a selective vascular endothelial growth factor receptor tyrosine kinase inhibitor, on experimental corneal neovascularization. | Ophthalmic research 20120101 |
| Normalization of the lymph node T cell stromal microenvironment in lpr/lpr mice is associated with SU5416-induced reduction in autoantibodies. | PloS one 20120101 |
| The soluble guanylate cyclase stimulator riociguat ameliorates pulmonary hypertension induced by hypoxia and SU5416 in rats. | PloS one 20120101 |
| SU5416, a VEGF receptor inhibitor and ligand of the AHR, represents a new alternative for immunomodulation. | PloS one 20120101 |
| Unexpected neuronal protection of SU5416 against 1-Methyl-4-phenylpyridinium ion-induced toxicity via inhibiting neuronal nitric oxide synthase. | PloS one 20120101 |
| Emerging therapies targeting tumor vasculature in multiple myeloma and other hematologic and solid malignancies. | Current cancer drug targets 20111101 |
| Clinical experience with antiangiogenic therapy in leukemia. | Current cancer drug targets 20111101 |
| Comprehensive assay of kinase catalytic activity reveals features of kinase inhibitor selectivity. | Nature biotechnology 20111101 |
| [The effects of VEGF-R inhibitor on podocytopathy of rats with type I diabetic nephropathy]. | Xi bao yu fen zi mian yi xue za zhi = Chinese journal of cellular and molecular immunology 20110901 |
| Semaphorin-PlexinD1 signaling limits angiogenic potential via the VEGF decoy receptor sFlt1. | Developmental cell 20110816 |
| SU5416 and EGCG work synergistically and inhibit angiogenic and survival factors and induce cell cycle arrest to promote apoptosis in human malignant neuroblastoma SH-SY5Y and SK-N-BE2 cells. | Neurochemical research 20110801 |
| Peptide-directed highly selective targeting of pulmonary arterial hypertension. | The American journal of pathology 20110601 |
| Virtual screening and further development of novel ALK inhibitors. | Bioorganic & medicinal chemistry 20110515 |
| Androgen stimulates endothelial cell proliferation via an androgen receptor/VEGF/cyclin A-mediated mechanism. | American journal of physiology. Heart and circulatory physiology 20110401 |
| Suppression of choroidal neovascularization by intravitreal injection of liposomal SU5416. | Archives of ophthalmology (Chicago, Ill. : 1960) 20110301 |
| The effects of antiangiogenic compound SU5416 in a rat model of pulmonary arterial hypertension. | Respiration; international review of thoracic diseases 20110101 |
| SU5416 induces premature senescence in endothelial progenitor cells from patients with age-related macular degeneration. | Molecular vision 20110101 |
| A novel xenograft model in zebrafish for high-resolution investigating dynamics of neovascularization in tumors. | PloS one 20110101 |
| Angiogenesis but not neurogenesis is critical for normal learning and memory acquisition. | Neuroscience 20101124 |
| Suppression of hypoxia-induced HIF-1alpha accumulation by VEGFR inhibitors: Different profiles of AAL993 versus SU5416 and KRN633. | Cancer letters 20101001 |
| Adrenergic receptor blockade reverses right heart remodeling and dysfunction in pulmonary hypertensive rats. | American journal of respiratory and critical care medicine 20100901 |
| Anti-vascular endothelial growth factor treatment in combination with chemotherapy delays hematopoietic recovery due to decreased proliferation of bone marrow hematopoietic progenitor cells. | Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 20100901 |
| Design, synthesis and evaluation of 2-amino-4-m-bromoanilino-6-arylmethyl-7H-pyrrolo[2,3-d]pyrimidines as tyrosine kinase inhibitors and antiangiogenic agents. | Bioorganic & medicinal chemistry 20100715 |
| Novel pyrazole derivatives: synthesis and evaluation of anti-angiogenic activity. | Bioorganic & medicinal chemistry 20100615 |
| The contribution of a 2-amino group on receptor tyrosine kinase inhibition and antiangiogenic activity in 4-anilinosubstituted pyrrolo[2,3-d]pyrimidines. | Bioorganic & medicinal chemistry letters 20100515 |
| Synthesis and biological activity of N(4)-phenylsubstituted-6-(2,4-dichloro phenylmethyl)-7H-pyrrolo[2,3-d]pyrimidine-2,4-diamines as vascular endothelial growth factor receptor-2 inhibitors and antiangiogenic and antitumor agents. | Bioorganic & medicinal chemistry 20100515 |
| TSU-16, (Z)-3-[(2,4-dimethylpyrrol-5-yl)methylidenyl]-2-indolinone, is a potent activator of aryl hydrocarbon receptor and increases CYP1A1 and CYP1A2 expression in human hepatocytes. | Chemico-biological interactions 20100415 |
| CREB activation mediates VEGF-A's protection of neurons and cerebral vascular endothelial cells. | Journal of neurochemistry 20100401 |
| Vascular endothelial growth factor is involved in mediating increased de novo hippocampal neurogenesis in response to traumatic brain injury. | Journal of neurotrauma 20100301 |
| Single agents with designed combination chemotherapy potential: synthesis and evaluation of substituted pyrimido[4,5-b]indoles as receptor tyrosine kinase and thymidylate synthase inhibitors and as antitumor agents. | Journal of medicinal chemistry 20100225 |
| Stimulation of sphingosine 1-phosphate signaling as an alveolar cell survival strategy in emphysema. | American journal of respiratory and critical care medicine 20100215 |
| Synthesis, structure-activity relationship and crystallographic studies of 3-substituted indolin-2-one RET inhibitors. | Bioorganic & medicinal chemistry 20100215 |
| Vascular endothelial growth factor receptor-2 inhibition promotes cell death and limits endothelial cell proliferation in a neonatal rodent model of stroke. | Stroke 20100201 |
| ERK1/2-dependent vascular endothelial growth factor signaling sustains cyst growth in polycystin-2 defective mice. | Gastroenterology 20100101 |
| Tumor secretion of VEGF induces endothelial cells to suppress T cell functions through the production of PGE2. | Journal of immunotherapy (Hagerstown, Md. : 1997) 20100101 |
| Synthesis and radiopharmacological investigation of 3-[4'-[(18)F]fluorobenzylidene]indolin-2-one as possible tyrosine kinase inhibitor. | Bioorganic & medicinal chemistry 20091115 |
| Reduction in endothelial tip cell filopodia corresponds to reduced intravitreous but not intraretinal vascularization in a model of ROP. | Experimental eye research 20091101 |
| Design, synthesis, and X-ray crystal structures of 2,4-diaminofuro[2,3-d]pyrimidines as multireceptor tyrosine kinase and dihydrofolate reductase inhibitors. | Bioorganic & medicinal chemistry 20091015 |
| Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum. | Nature chemical biology 20091001 |
| Vascular endothelial growth factor receptor inhibitor enhances dietary salt-induced hypertension in Sprague-Dawley rats. | American journal of physiology. Regulatory, integrative and comparative physiology 20090701 |
| Genetic evidence for a noncanonical function of seryl-tRNA synthetase in vascular development. | Circulation research 20090605 |
| VEGF and angiogenesis in acute and chronic MOG((35-55)) peptide induced EAE. | Journal of neuroimmunology 20090430 |
| Oral administration of pyrrolidine dithiocarbamate (PDTC) inhibits VEGF expression, tumor angiogenesis, and growth of breast cancer in female mice. | Cancer biology & therapy 20090315 |
| VEGFR1 receptor tyrosine kinase localization to the Golgi apparatus is calcium-dependent. | Experimental cell research 20090310 |
| Phase I study of SU5416, a small molecule inhibitor of the vascular endothelial growth factor receptor (VEGFR) in refractory pediatric central nervous system tumors. | Pediatric blood & cancer 20090201 |
| VEGFR-2 antagonist SU5416 attenuates bleomycin-induced pulmonary fibrosis in mice. | International immunopharmacology 20090101 |
| Ligation or cross-linking of CD40 has different effects on AGS gastric cancer cells. | Cellular immunology 20090101 |
| Antiangiogenic cancer therapy using tumor vasculature-targeted liposomes encapsulating 3-(3,5-dimethyl-1H-pyrrol-2-ylmethylene)-1,3-dihydro-indol-2-one, SU5416. | Cancer letters 20081108 |
| Antiangiogenic and anticolorectal cancer effects of metronomic irinotecan chemotherapy alone and in combination with semaxinib. | British journal of cancer 20080520 |
| Design, synthesis and biological evaluation of substituted pyrrolo[2,3-d]pyrimidines as multiple receptor tyrosine kinase inhibitors and antiangiogenic agents. | Bioorganic & medicinal chemistry 20080515 |
| Combination of vascular endothelial growth factor receptor/platelet-derived growth factor receptor inhibition markedly improves radiation tumor therapy. | Clinical cancer research : an official journal of the American Association for Cancer Research 20080401 |
| Impaired VEGF and nitric oxide signaling after nitrofen exposure in rat fetal lung explants. | American journal of physiology. Lung cellular and molecular physiology 20080101 |
| Should tumor VEGF expression influence decisions on combining low-dose chemotherapy with antiangiogenic therapy? Preclinical modeling in ovarian cancer. | Journal of translational medicine 20080101 |
| Targeting the vascular endothelial growth factor system to prevent ovarian hyperstimulation syndrome. | Human reproduction update 20080101 |
| Inhibition of choroidal neovascularization by blocking vascular endothelial growth factor receptor tyrosine kinase. | Japanese journal of ophthalmology 20080101 |
| Development of an intravenous formulation of SU010382 (prodrug of SU5416, an anti-angiogenesis agent). | PDA journal of pharmaceutical science and technology 20080101 |
| VEGF modulation of retinal pigment epithelium resistance. | Experimental eye research 20071201 |
| Role of NADPH oxidase and ANG II in diabetes-induced retinal leukostasis. | American journal of physiology. Regulatory, integrative and comparative physiology 20071001 |
| Effect of chemical stabilizers of hypoxia-inducible factors on early lung development. | American journal of physiology. Lung cellular and molecular physiology 20070901 |
| Semaxinib (SU5416) as a therapeutic agent targeting oncogenic Kit mutants resistant to imatinib mesylate. | Oncogene 20070531 |
| A Phase II study of SU5416 in patients with advanced or recurrent head and neck cancers. | Investigational new drugs 20070401 |
| Rho kinase-mediated vasoconstriction is important in severe occlusive pulmonary arterial hypertension in rats. | Circulation research 20070330 |
| Synthesis and evaluation of prodrugs for anti-angiogenic pyrrolylmethylidenyl oxindoles. | Bioorganic & medicinal chemistry letters 20070315 |
| Effects of vascular endothelial growth factor receptor inhibitor SU5416 and prostacyclin on murine lung metastasis. | Anti-cancer drugs 20070301 |
| A phase II, pharmacokinetic, and biologic study of semaxanib and thalidomide in patients with metastatic melanoma. | Cancer chemotherapy and pharmacology 20070201 |
| [Clinical importance of angiogenesis and angiogenic factors in oncohematology]. | Wiadomosci lekarskie (Warsaw, Poland : 1960) 20070101 |
| Downregulation of VEGF-A, STAT5 and AKT in acute myeloid leukemia blasts of patients treated with SU5416. | Leukemia & lymphoma 20061201 |
| Blockade of vascular endothelial growth factor signaling ameliorates diabetic albuminuria in mice. | Journal of the American Society of Nephrology : JASN 20061101 |
| Simvastatin causes endothelial cell apoptosis and attenuates severe pulmonary hypertension. | American journal of physiology. Lung cellular and molecular physiology 20061001 |
| An orally administered multitarget tyrosine kinase inhibitor, SU11248, is a novel potent inhibitor of thyroid oncogenic RET/papillary thyroid cancer kinases. | The Journal of clinical endocrinology and metabolism 20061001 |
| Structure-activity-relationship studies of conformationally restricted analogs of combretastatin A-4 derived from SU5416. | Bioorganic & medicinal chemistry 20061001 |
| Inhibition of RET tyrosine kinase by SU5416. | Journal of molecular endocrinology 20061001 |
| [Recent advances in the study of pharmacological activities and solid-phase synthesis of indoles and their analogues]. | Yao xue xue bao = Acta pharmaceutica Sinica 20060801 |
| Antiangiogenic combination tumor therapy blocking alpha(v)-integrins and VEGF-receptor-2 increases therapeutic effects in vivo. | International journal of cancer 20060715 |
| A phase I study with oral SU5416 in patients with advanced solid tumors: a drug inducing its clearance. | Investigational new drugs 20060701 |
| VEGF-C promotes survival in podocytes. | American journal of physiology. Renal physiology 20060701 |
| Vascular endothelial growth factor and hepatocyte regeneration in acetaminophen toxicity. | American journal of physiology. Gastrointestinal and liver physiology 20060701 |
| Anti-angiogenic and anti-HER therapy. | Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie 20060701 |
| Novel bis(1H-indol-2-yl)methanones as potent inhibitors of FLT3 and platelet-derived growth factor receptor tyrosine kinase. | Journal of medicinal chemistry 20060601 |
| Microsphere-based protease assays and screening application for lethal factor and factor Xa. | Cytometry. Part A : the journal of the International Society for Analytical Cytology 20060501 |
| Phase I/pilot study of SU5416 (semaxinib) in combination with irinotecan/bolus 5-FU/LV (IFL) in patients with metastatic colorectal cancer. | American journal of clinical oncology 20060401 |
| Distribution, metabolism, and excretion of the anti-angiogenic compound SU5416. | Toxicology in vitro : an international journal published in association with BIBRA 20060301 |
| Emerging Flt3 kinase inhibitors in the treatment of leukaemia. | Expert opinion on emerging drugs 20060301 |
| A Phase I study of escalating doses of the tyrosine kinase inhibitor semaxanib (SU5416) in combination with irinotecan in patients with advanced colorectal carcinoma. | Japanese journal of clinical oncology 20060201 |
| Clinical implications for vascular endothelial growth factor in the lung: friend or foe? | Respiratory research 20060101 |
| Conformationally restricted analogs of Combretastatin A-4 derived from SU5416. | Bioorganic & medicinal chemistry letters 20051215 |
| Enhancing the therapeutic responsiveness of photodynamic therapy with the antiangiogenic agents SU5416 and SU6668 in murine nasopharyngeal carcinoma models. | Cancer chemotherapy and pharmacology 20051201 |
| Nerve growth factor-induced migration of endothelial cells. | The Journal of pharmacology and experimental therapeutics 20051201 |
| A Phase I study of the angiogenesis inhibitor SU5416 (semaxanib) in solid tumours, incorporating dynamic contrast MR pharmacodynamic end points. | British journal of cancer 20051017 |
| Functional CT for quantifying tumor perfusion in antiangiogenic therapy in a rat model. | Radiology 20051001 |
| Indolin-2-ones with high in vivo efficacy in a model for multiple sclerosis. | Journal of medicinal chemistry 20050825 |
| Initial apoptosis is followed by increased proliferation of apoptosis-resistant endothelial cells. | FASEB journal : official publication of the Federation of American Societies for Experimental Biology 20050701 |
| In vitro procoagulant activity induced in endothelial cells by chemotherapy and antiangiogenic drug combinations: modulation by lower-dose chemotherapy. | Cancer research 20050615 |
| [Potential pharmacological treatments for diabetic retinopathy]. | Nihon rinsho. Japanese journal of clinical medicine 20050601 |
| [Medications for diabetic macular edema]. | Nihon rinsho. Japanese journal of clinical medicine 20050601 |
| Vascular endothelial growth factor: a therapeutic target for tumors of the Ewing's sarcoma family. | Clinical cancer research : an official journal of the American Association for Cancer Research 20050315 |
| C-kit as a target in the treatment of acute myelogenous leukemia. | Current hematology reports 20050101 |
| Differential roles of vascular endothelial growth factor receptors 1 and 2 in dendritic cell differentiation. | Journal of immunology (Baltimore, Md. : 1950) 20050101 |
| Emphysema: an autoimmune vascular disease? | Proceedings of the American Thoracic Society 20050101 |
| Triple combination of irradiation, chemotherapy (pemetrexed), and VEGFR inhibition (SU5416) in human endothelial and tumor cells. | International journal of radiation oncology, biology, physics 20041115 |
| SU5416 inhibited VEGF and HIF-1alpha expression through the PI3K/AKT/p70S6K1 signaling pathway. | Biochemical and biophysical research communications 20041112 |
| c-Myc interacts with hypoxia to induce angiogenesis in vivo by a vascular endothelial growth factor-dependent mechanism. | Cancer research 20040915 |
| Antiangiogenic versus cytotoxic therapeutic approaches to human pancreas cancer: an experimental study with a vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor and gemcitabine. | European journal of pharmacology 20040913 |
| Vascular endothelial growth factor in diabetes induced early retinal abnormalities. | Diabetes research and clinical practice 20040901 |
| Phase II study of the antiangiogenic agent SU5416 in patients with advanced soft tissue sarcomas. | Clinical cancer research : an official journal of the American Association for Cancer Research 20040901 |
| SU5416 is a potent inhibitor of hepatocyte growth factor receptor (c-Met) and blocks HGF-induced invasiveness of human HepG2 hepatoma cells. | Journal of hepatology 20040801 |
| Effects of SU5416, a small molecule tyrosine kinase receptor inhibitor, on FLT3 expression and phosphorylation in patients with refractory acute myeloid leukemia. | Leukemia research 20040701 |
| Phase II study of the Flk-1 tyrosine kinase inhibitor SU5416 in advanced melanoma. | Clinical cancer research : an official journal of the American Association for Cancer Research 20040615 |
| Determination of SU5416, a novel angiogenesis inhibitor, in human plasma by liquid chromatography. | Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20040605 |
| The c-Cbl/CD2AP complex regulates VEGF-induced endocytosis and degradation of Flt-1 (VEGFR-1). | FASEB journal : official publication of the Federation of American Societies for Experimental Biology 20040501 |
| The vascular endothelial growth factor (VEGF) receptor Flt-1 (VEGFR-1) modulates Flk-1 (VEGFR-2) signaling during blood vessel formation. | The American journal of pathology 20040501 |
| [Lung cancer: molecular targeting therapy]. | Nihon Kokyuki Gakkai zasshi = the journal of the Japanese Respiratory Society 20040501 |
| New cancer therapeutics: target-specific in, cytotoxics out? | Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy 20040401 |
| Anti-vascular tumor therapy: recent advances, pitfalls and clinical perspectives. | Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy 20040401 |
| N-acetylcysteine treatment protects against VEGF-receptor blockade-related emphysema. | COPD 20040401 |
| Antiangiogenic therapy for von Hippel-Lindau disease. | JAMA 20040225 |
| Combined inhibition of VEGF and PDGF signaling enforces tumor vessel regression by interfering with pericyte-mediated endothelial cell survival mechanisms. | FASEB journal : official publication of the Federation of American Societies for Experimental Biology 20040201 |
| Plasma and cerebrospinal fluid pharmacokinetics of SU5416 after intravenous administration in nonhuman primates. | Cancer chemotherapy and pharmacology 20040101 |
| Phase II study of SU5416, a small molecule vascular endothelial growth factor tyrosine kinase receptor inhibitor, in patients with refractory multiple myeloma. | Clinical cancer research : an official journal of the American Association for Cancer Research 20040101 |
| Complete radiological and metabolic response of metastatic renal cell carcinoma to SU5416 (semaxanib) in a patient with probable von Hippel-Lindau syndrome. | Urologic oncology 20040101 |
| Combined therapy with direct and indirect angiogenesis inhibition results in enhanced antiangiogenic and antitumor effects. | Cancer research 20031215 |
| SU5416 plus interferon alpha in advanced renal cell carcinoma: a phase II California Cancer Consortium Study with biological and imaging correlates of angiogenesis inhibition. | Clinical cancer research : an official journal of the American Association for Cancer Research 20031015 |
| Human NADPH-cytochrome p450 reductase overexpression does not enhance the aerobic cytotoxicity of doxorubicin in human breast cancer cell lines. | Cancer research 20031015 |
| The antiangiogenic agent SU5416 down-regulates phorbol ester-mediated induction of cyclooxygenase 2 expression by inhibiting nicotinamide adenine dinucleotide phosphate oxidase activity. | Cancer research 20031015 |
| Suppression of experimental choroidal neovascularization utilizing KDR selective receptor tyrosine kinase inhibitor. | Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie 20030901 |
| SU5416, a small molecule tyrosine kinase receptor inhibitor, has biologic activity in patients with refractory acute myeloid leukemia or myelodysplastic syndromes. | Blood 20030801 |
| Research retreat: Pfizer eliminates Sugen, shrinks cancer infrastructure. | Journal of the National Cancer Institute 20030716 |
| Oxidative stress and apoptosis interact and cause emphysema due to vascular endothelial growth factor receptor blockade. | American journal of respiratory cell and molecular biology 20030701 |
| Treatment of von Hippel-Lindau retinal hemangioblastoma by the vascular endothelial growth factor receptor inhibitor SU5416 is more effective for associated macular edema than for hemangioblastomas. | American journal of ophthalmology 20030701 |
| SU5416 and SU6668 attenuate the angiogenic effects of radiation-induced tumor cell growth factor production and amplify the direct anti-endothelial action of radiation in vitro. | Cancer research 20030701 |
| SU5416 selectively impairs angiogenesis to induce prostate cancer-specific apoptosis. | Molecular cancer therapeutics 20030701 |
| Pharmacodynamic-mediated effects of the angiogenesis inhibitor SU5416 on the tumor disposition of temozolomide in subcutaneous and intracerebral glioma xenograft models. | The Journal of pharmacology and experimental therapeutics 20030601 |
| Potential role of platelets in endothelial damage observed during treatment with cisplatin, gemcitabine, and the angiogenesis inhibitor SU5416. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20030601 |
| Potential inhibitors of angiogenesis. Part I: 3-(imidazol-4(5)-ylmethylene)indolin-2-ones. | Journal of enzyme inhibition and medicinal chemistry 20030601 |
| Potential inhibitors of angiogenesis. Part II: 3-(azolylmethylene)-2,3-dihydrobenzo[b]furan-2-ones. | Journal of enzyme inhibition and medicinal chemistry 20030601 |
| Vascular endothelial growth factor (VEGF) receptor-2 signaling mediates VEGF-C(deltaNdeltaC)- and VEGF-A-induced angiogenesis in vitro. | Experimental cell research 20030501 |
| Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors. | The Journal of clinical investigation 20030501 |
| Efficacy and toxicity of the angiogenesis inhibitor SU5416 as a single agent in patients with advanced renal cell carcinoma, melanoma, and soft tissue sarcoma. | Clinical cancer research : an official journal of the American Association for Cancer Research 20030501 |
| Phase II study of SU5416--a small-molecule, vascular endothelial growth factor tyrosine-kinase receptor inhibitor--in patients with refractory myeloproliferative diseases. | Cancer 20030415 |
| [From molecular biology to new treatment approaches to colorectal cancer: basic research, experimental trials and surgical implications]. | Il Giornale di chirurgia 20030401 |
| Discovery of 5-[5-fluoro-2-oxo-1,2- dihydroindol-(3Z)-ylidenemethyl]-2,4- dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide, a novel tyrosine kinase inhibitor targeting vascular endothelial and platelet-derived growth factor receptor tyrosine kinase. | Journal of medicinal chemistry 20030327 |
| Effect of angiogenesis inhibitors on oestrogen-mediated endometrial endothelial cell proliferation in the ovariectomized mouse. | Reproduction (Cambridge, England) 20030301 |
| Improved effect of an antiangiogenic tyrosine kinase inhibitor (SU5416) by combinations with fractionated radiotherapy or low molecular weight heparin. | Neoplasia (New York, N.Y.) 20030301 |
| [Perspectives on the oncologist pharmacopoeia]. | Bulletin du cancer 20030101 |
| Expression profiling of blood samples from an SU5416 Phase III metastatic colorectal cancer clinical trial: a novel strategy for biomarker identification. | BMC cancer 20030101 |
| Flt3 in acute myelogenous leukemia: biology, prognosis, and therapeutic implications. | Medical oncology (Northwood, London, England) 20030101 |
| Anthranilic acid amides: a novel class of antiangiogenic VEGF receptor kinase inhibitors. | Journal of medicinal chemistry 20021219 |
| Synthetic lethality: killing cancer with cancer. | Journal of the National Cancer Institute 20021120 |
| Zebrafish: a preclinical model for drug screening. | Assay and drug development technologies 20021101 |
| SU5416 and SU5614 inhibit kinase activity of wild-type and mutant FLT3 receptor tyrosine kinase. | Blood 20021015 |
| Inhibitors of the vascular endothelial growth factor receptor. | Hematology/oncology clinics of North America 20021001 |
| New drugs in acute myeloid leukemia. | Current oncology reports 20020901 |
| Rapid and durable recovery of visual function in a patient with von hippel-lindau syndrome after systemic therapy with vascular endothelial growth factor receptor inhibitor su5416. | Ophthalmology 20020901 |
| Results of a Phase I dose-escalating study of the antiangiogenic agent, SU5416, in patients with advanced malignancies. | Clinical cancer research : an official journal of the American Association for Cancer Research 20020901 |
| Targeting vascular endothelial growth factor in colorectal cancer. | Oncology (Williston Park, N.Y.) 20020801 |
| A novel dihydroxanthenone, AGI-B4 with inhibition of VEGF-induced endothelial cell growth. | The Journal of antibiotics 20020701 |
| Vascular endothelial growth factor-mediated angiogenesis inhibition and postoperative wound healing in rats. | The Journal of surgical research 20020601 |
| Orthogonal polarisation spectral imaging as a new tool for the assessment of antivascular tumour treatment in vivo: a validation study. | British journal of cancer 20020520 |
| CHS 828 inhibits neuroblastoma growth in mice alone and in combination with antiangiogenic drugs. | Pediatric research 20020501 |
| Sustained ER Ca2+ depletion suppresses protein synthesis and induces activation-enhanced cell death in mast cells. | The Journal of biological chemistry 20020419 |
| Unexpected serious toxicity with chemotherapy and antiangiogenic combinations: time to take stock! | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20020315 |
| Dose-finding and pharmacokinetic study of cisplatin, gemcitabine, and SU5416 in patients with solid tumors. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20020315 |
| Inhibition of KIT tyrosine kinase activity: a novel molecular approach to the treatment of KIT-positive malignancies. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20020315 |
| Antiangiogenic effect by SU5416 is partly attributable to inhibition of Flt-1 receptor signaling. | Molecular cancer therapeutics 20020301 |
| SU5416 delays wound healing through inhibition of TGF-beta 1 activation. | Cancer biology & therapy 20020101 |
| New chemotherapeutic agents: update of major chemoradiation trials in solid tumors. | Oncology 20020101 |
| Comparative study of isoflavone, quinoxaline and oxindole families of anti-angiogenic agents. | Angiogenesis 20020101 |
| Combining antiangiogenic agents with metronomic chemotherapy enhances efficacy against late-stage pancreatic islet carcinomas in mice. | Cold Spring Harbor symposia on quantitative biology 20020101 |
| Importance of vascular endothelial growth factor A in the progression of experimental neuroblastoma. | Angiogenesis 20020101 |
| Sequential tumor biopsies in early phase clinical trials of anticancer agents for pharmacodynamic evaluation. | Clinical cancer research : an official journal of the American Association for Cancer Research 20011001 |
| Flk-1 specific kinase inhibitor (SU5416) inhibited the growth of GS-9L glioma in rat brain and prolonged the survival. | The Kobe journal of medical sciences 20010801 |
| Simultaneous determination of SU5416 and its phase I and phase II metabolites in rat and dog plasma by LC/MS/MS. | Journal of pharmaceutical and biomedical analysis 20010701 |
| Stable remission after administration of the receptor tyrosine kinase inhibitor SU5416 in a patient with refractory acute myeloid leukemia. | Blood 20010701 |
| Magnetic resonance imaging of ethyl-nitrosourea-induced rat gliomas: a model for experimental therapeutics of low-grade gliomas. | Journal of neuro-oncology 20010701 |
| Indolinone tyrosine kinase inhibitors block Kit activation and growth of small cell lung cancer cells. | Cancer research 20010501 |
| Nonvascular role for VEGF: VEGFR-1, 2 activity is critical for neural retinal development. | FASEB journal : official publication of the Federation of American Societies for Experimental Biology 20010501 |
| [Tumor angiogenesis and tumor angiogenesis inhibitors]. | Gan to kagaku ryoho. Cancer & chemotherapy 20010501 |
| The antiangiogenic protein kinase inhibitors SU5416 and SU6668 inhibit the SCF receptor (c-kit) in a human myeloid leukemia cell line and in acute myeloid leukemia blasts. | Blood 20010301 |
| The vascular endothelial growth factor (VEGF) signaling pathway: a therapeutic target in patients with hematologic malignancies. | The oncologist 20010101 |
| Endothelial survival factors as targets for antineoplastic therapy. | Cancer journal (Sudbury, Mass.) 20010101 |
| Role of angiogenesis inhibitors in acute myeloid leukemia. | Cancer journal (Sudbury, Mass.) 20010101 |
| Identification of substituted 3-[(4,5,6, 7-tetrahydro-1H-indol-2-yl)methylene]-1,3-dihydroindol-2-ones as growth factor receptor inhibitors for VEGF-R2 (Flk-1/KDR), FGF-R1, and PDGF-Rbeta tyrosine kinases. | Journal of medicinal chemistry 20000713 |
| New anilinophthalazines as potent and orally well absorbed inhibitors of the VEGF receptor tyrosine kinases useful as antagonists of tumor-driven angiogenesis. | Journal of medicinal chemistry 20000615 |
| Design, synthesis, and evaluations of substituted 3-[(3- or 4-carboxyethylpyrrol-2-yl)methylidenyl]indolin-2-ones as inhibitors of VEGF, FGF, and PDGF receptor tyrosine kinases. | Journal of medicinal chemistry 19991216 |
| Synthesis and biological evaluations of 3-substituted indolin-2-ones: a novel class of tyrosine kinase inhibitors that exhibit selectivity toward particular receptor tyrosine kinases. | Journal of medicinal chemistry 19980702 |
Related Products
Featured Products
© 2019 Angene International Limited. All rights Reserved.